PULMONARY DRUG DELIVERY SYSTEMS MARKET ANALYSIS

Market Challenges And Opportunities

Global Pulmonary Drug Delivery Systems Market– Driver

Increasing prevalance of chronic disorder

Increasing changes in lifestyles is considered a major cause of various chronic disorders, such as diabetes, functional gastrointestinal disorder, eczema, arthritis, asthma, cancer, chronic obstructive pulmonary disease, and others. Thus, the increasing prevalence of chronic disorders globally is expected to boost the growth of the market over the forecast period. For instance, according to the data published by September 2022, the Forum of International Respiratory Societies (FIRS), Global Impact of Respiratory Disease report, an estimated 200 million people has COPD, of which about 3.2 million die each year, making it the third-leading cause of death worldwide, moreover, more than 2.2 million new cases of lung cancer in 2020 and 1.80 million deaths, globally, lung cancer is responsible for 1 in 4 cancer death.

Increasing products launches by the market players

Increasing number of product launches by the market players due to numerous advantages associated with the pulmonary drug delivery systems is expected to foster the market growth over the forecast period. For instance, in July 2020, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, announced that it has launched a bluetooth-enabled version of its ProAir albuterol sulfate rescue inhaler. The ProAir Digihaler’s sensors connect to a companion mobile app to provide inhaler-use information to healthcare providers. The new inhaler was available by prescription to U.S. patients age 4 and older. Global Pulmonary Drug Delivery Systems Market: Restraints

Stringent regulatory scenario

Stringent regulatory scenario is expected to hinder growth of the market. Regulatory requirements for pulmonary drug delivery systems are quite challenging as MDIs and DPIs are considered as drug-device combination products, and therefore, are regulated under new provisions by the drug regulatory authorities due to the following factors:

• Product performance is the combination of individual function of both device and drug formulation
• Product operating technique may affect the dose administration
• Product manufacturing and use have significant impact on environment

Moreover, various mechanical, chemical, and immunological barriers along with behavioral barriers of poor adherence and poor inhaler technique also limit growth of the market.

The stringent rule and regulation can affect the market growth but if manufacturer follow the rule and regulation during manufacturing of product it helps to maintain the quality of the product thus it is necessary to follow the rules and regulation during manufacturing.